多发性硬化相关的发作性运动诱发性运动障碍：对拉科酰胺的长期良好反应。 - Suppr

Multiple Sclerosis-Related Paroxysmal Kinesigenic Dyskinesia: Long Term, Favorable Response to Lacosamide.

作者信息

Poulidou Vasiliki, Spilioti Martha, Moschou Maria, Papanikolaou Nickolas, Drevelegas Antonios, Papagiannopoulos Sotirios, Kazis Dimitrios, Kimiskidis Vasilios K

机构信息

1st Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Computational Clinical Imaging Group, Centre for the Unknown, Champalimaud Foundation, Lisbon, Portugal; Royal Marsden, London, UK; The Institute of Cancer Research, London, UK; Karolinska Institute, Sweden; Institute of Computer Science, The Foundation f.

出版信息

J Mov Disord. 2022 Sep;15(3):286-289. doi: 10.14802/jmd.22016. Epub 2022 Jul 26.

DOI:10.14802/jmd.22016

PMID:35880380

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9536912/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b37/9536912/933299224dfa/jmd-22016f1.jpg

相似文献

Multiple Sclerosis-Related Paroxysmal Kinesigenic Dyskinesia: Long Term, Favorable Response to Lacosamide.

J Mov Disord. 2022 Sep;15(3):286-289. doi: 10.14802/jmd.22016. Epub 2022 Jul 26.

Paroxysmal Kinesigenic Dyskinesia as the Presenting and Only Manifestation of Multiple Sclerosis after Eighteen Months of Follow-Up.

J Mov Disord. 2017 May;10(2):96-98. doi: 10.14802/jmd.16055. Epub 2017 Mar 24.

Proline-rich transmembrane protein 2-negative paroxysmal kinesigenic dyskinesia: Clinical and genetic analyses of 163 patients.

Mov Disord. 2018 Mar;33(3):459-467. doi: 10.1002/mds.27274. Epub 2018 Jan 22.

Lacosamide for children with paroxysmal kinesigenic dyskinesia.

Brain Dev. 2020 Sep;42(8):617-620. doi: 10.1016/j.braindev.2020.04.009. Epub 2020 May 16.

16p11.2 deletion in patients with paroxysmal kinesigenic dyskinesia but without intellectual disability.

Brain Behav. 2018 Nov;8(11):e01134. doi: 10.1002/brb3.1134. Epub 2018 Oct 11.

Clinical characteristics and PRRT2 gene mutation analysis of sporadic patients with paroxysmal kinesigenic dyskinesia in China.

Clin Neurol Neurosurg. 2017 Aug;159:25-28. doi: 10.1016/j.clineuro.2017.05.004. Epub 2017 May 8.

The Phenotypic and Genetic Spectrum of Paroxysmal Kinesigenic Dyskinesia in China.

Mov Disord. 2020 Aug;35(8):1428-1437. doi: 10.1002/mds.28061. Epub 2020 May 11.

Clinical commentary on "Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis" and "Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients".

Mult Scler. 2017 Nov;23(13):1797-1798. doi: 10.1177/1352458517702555. Epub 2017 Apr 11.

Clinical and polygraphic study of familial paroxysmal kinesigenic dyskinesia with PRRT2 mutation.

Epileptic Disord. 2013 Jun;15(2):123-7. doi: 10.1684/epd.2013.0569.

Altered inhibitory modulation of somatosensory cortices in paroxysmal kinesigenic dyskinesia.

Mov Disord. 2013 Oct;28(12):1728-31. doi: 10.1002/mds.25656. Epub 2013 Sep 20.

本文引用的文献

Pharmacology of lacosamide: From its molecular mechanisms and pharmacokinetics to future therapeutic applications.

Life Sci. 2021 Jun 15;275:119342. doi: 10.1016/j.lfs.2021.119342. Epub 2021 Mar 11.

Lacosamide for children with paroxysmal kinesigenic dyskinesia.

Brain Dev. 2020 Sep;42(8):617-620. doi: 10.1016/j.braindev.2020.04.009. Epub 2020 May 16.

Lesion correlates of secondary paroxysmal dyskinesia in multiple sclerosis.

J Neurol. 2018 Oct;265(10):2277-2283. doi: 10.1007/s00415-018-8989-2. Epub 2018 Jul 31.

Neuromyelitis optica spectrum disorder related tonic spasms responsive to lacosamide.

Mult Scler Relat Disord. 2017 Apr;13:73-74. doi: 10.1016/j.msard.2017.02.009. Epub 2017 Feb 14.

Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.

Mult Scler. 2017 Nov;23(13):1791-1795. doi: 10.1177/1352458517702968. Epub 2017 Apr 11.

Axonal conduction and injury in multiple sclerosis: the role of sodium channels.

Nat Rev Neurosci. 2006 Dec;7(12):932-41. doi: 10.1038/nrn2023.

Paroxysmal attacks in multiple sclerosis.

Brain. 1975 Jun;98(2):189-202. doi: 10.1093/brain/98.2.189.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Multiple Sclerosis-Related Paroxysmal Kinesigenic Dyskinesia: Long Term, Favorable Response to Lacosamide.

作者信息

Poulidou Vasiliki, Spilioti Martha, Moschou Maria, Papanikolaou Nickolas, Drevelegas Antonios, Papagiannopoulos Sotirios, Kazis Dimitrios, Kimiskidis Vasilios K

机构信息

1st Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

出版信息

J Mov Disord. 2022 Sep;15(3):286-289. doi: 10.14802/jmd.22016. Epub 2022 Jul 26.

DOI:10.14802/jmd.22016

PMID:35880380

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9536912/

Abstract

摘要

相似文献

Multiple Sclerosis-Related Paroxysmal Kinesigenic Dyskinesia: Long Term, Favorable Response to Lacosamide.

J Mov Disord. 2022 Sep;15(3):286-289. doi: 10.14802/jmd.22016. Epub 2022 Jul 26.

Paroxysmal Kinesigenic Dyskinesia as the Presenting and Only Manifestation of Multiple Sclerosis after Eighteen Months of Follow-Up.

J Mov Disord. 2017 May;10(2):96-98. doi: 10.14802/jmd.16055. Epub 2017 Mar 24.

Proline-rich transmembrane protein 2-negative paroxysmal kinesigenic dyskinesia: Clinical and genetic analyses of 163 patients.

Mov Disord. 2018 Mar;33(3):459-467. doi: 10.1002/mds.27274. Epub 2018 Jan 22.

Lacosamide for children with paroxysmal kinesigenic dyskinesia.

Brain Dev. 2020 Sep;42(8):617-620. doi: 10.1016/j.braindev.2020.04.009. Epub 2020 May 16.

16p11.2 deletion in patients with paroxysmal kinesigenic dyskinesia but without intellectual disability.

Brain Behav. 2018 Nov;8(11):e01134. doi: 10.1002/brb3.1134. Epub 2018 Oct 11.

Clinical characteristics and PRRT2 gene mutation analysis of sporadic patients with paroxysmal kinesigenic dyskinesia in China.

Clin Neurol Neurosurg. 2017 Aug;159:25-28. doi: 10.1016/j.clineuro.2017.05.004. Epub 2017 May 8.

The Phenotypic and Genetic Spectrum of Paroxysmal Kinesigenic Dyskinesia in China.

Mov Disord. 2020 Aug;35(8):1428-1437. doi: 10.1002/mds.28061. Epub 2020 May 11.

Mult Scler. 2017 Nov;23(13):1797-1798. doi: 10.1177/1352458517702555. Epub 2017 Apr 11.

Clinical and polygraphic study of familial paroxysmal kinesigenic dyskinesia with PRRT2 mutation.

Epileptic Disord. 2013 Jun;15(2):123-7. doi: 10.1684/epd.2013.0569.

Altered inhibitory modulation of somatosensory cortices in paroxysmal kinesigenic dyskinesia.

Mov Disord. 2013 Oct;28(12):1728-31. doi: 10.1002/mds.25656. Epub 2013 Sep 20.

本文引用的文献

Pharmacology of lacosamide: From its molecular mechanisms and pharmacokinetics to future therapeutic applications.

Life Sci. 2021 Jun 15;275:119342. doi: 10.1016/j.lfs.2021.119342. Epub 2021 Mar 11.

Lacosamide for children with paroxysmal kinesigenic dyskinesia.

Brain Dev. 2020 Sep;42(8):617-620. doi: 10.1016/j.braindev.2020.04.009. Epub 2020 May 16.

Lesion correlates of secondary paroxysmal dyskinesia in multiple sclerosis.

J Neurol. 2018 Oct;265(10):2277-2283. doi: 10.1007/s00415-018-8989-2. Epub 2018 Jul 31.

Neuromyelitis optica spectrum disorder related tonic spasms responsive to lacosamide.

Mult Scler Relat Disord. 2017 Apr;13:73-74. doi: 10.1016/j.msard.2017.02.009. Epub 2017 Feb 14.

Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.

Mult Scler. 2017 Nov;23(13):1791-1795. doi: 10.1177/1352458517702968. Epub 2017 Apr 11.

Axonal conduction and injury in multiple sclerosis: the role of sodium channels.

Nat Rev Neurosci. 2006 Dec;7(12):932-41. doi: 10.1038/nrn2023.

Paroxysmal attacks in multiple sclerosis.

Brain. 1975 Jun;98(2):189-202. doi: 10.1093/brain/98.2.189.

Multiple Sclerosis-Related Paroxysmal Kinesigenic Dyskinesia: Long Term, Favorable Response to Lacosamide.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Multiple Sclerosis-Related Paroxysmal Kinesigenic Dyskinesia: Long Term, Favorable Response to Lacosamide.

作者信息

机构信息

出版信息

相似文献

本文引用的文献